CRF news

Elevated risk of Parkinson’s disease among people with type 2 diabetes appears to be reduced by some medications used to treat their diabetes, finds a new study led by UCL researchers.

Almost 5,000 people have been recruited to Covid-19 research studies at UCLH since the pandemic began, with recruitment to studies continuing.

A cancer drug trialled for the first time in the world at the UCLH Clinical Research Facility (CRF) has been approved for use in patients in the United States.

UCLH is to trial a COVID-19 vaccine developed by Imperial College London.

90% of people have a positive experience of taking part in UCLH research according to the latest Patient Research Experience Survey.

A new clinical trial investigating whether immunotherapy drug Ustekinumab could help to preserve insulin-producing cells in adolescents with newly diagnosed Type 1 diabetes (T1D) is now open at the NIHR UCLH Clinical Research Facility.

A drug company has announced positive results in the first global trial of a drug for a rare neuromuscular disease Friedreich’s ataxia (FA) which included patients from UCLH.

Researchers at UCL Queen Square Institute of Neurology (IoN) and the UCLH National Hospital for Neurology & Neurosurgery (NHNN) are set to test whether a drug can slow progression of the devastating neurodegenerative condition Multiple System Atrophy (MSA).

Researchers at UCLH have begun to test whether a drug can stop the growth of tumours in chordoma, a rare bone cancer which affects the spine.